MedTrace Logo

A New System for GERD Diagnosis and Treatment

NCT03600974 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2019-02-05

No results posted yet for this study

Summary

This is a pilot study measuring a new diagnosis and treatment system "EAISMLP" in adult patients with gastroesophageal reflux disease (GERD).

Conditions

  • GERD

Interventions

PROCEDURE

Stretta

Stretta for Endoscopy-E(+),Acid-A(+),Reflux-symptom association-S(+) or lower oesophageal sphincter-L(+) group

PROCEDURE

Laparoscopic Nissen fundoplication

Laparoscopic Nissen fundoplication for E(+),A(+) or L(+) group

DRUG

Probiotic Agent

Probiotic Agent for I(+)G/W；Live Bacillus Licheniformis Cranules 0.5g bid； Bifidbacterium 0.63g bid

DRUG

PPI

PPIs for A(+),E(+)or S(+) patients: Nexium 20mg Qd/Bid;Lansoprazole 30mg Qd/Bid；omeprazole 10mg-30mg Qd-Bid;Rabeprazole 10mg Qd/Bid;Esomeprazole 20mg Qd/Bid;Pantoprazole 40mg Qd/Bid

DRUG

Prokinetic Motility Agents

Prokinetic Motility Agents for M(+) group; Mosapride 5mg Tid; Domperidone 10mg Tid

DRUG

Neuromodulators

Neuromodulators for P(+) or S(+);Flupentixol and Melitracen 1# bid;

Sponsors & Collaborators

  • Capital Medical University

    lead OTHER

Principal Investigators

  • Chuan Zhang, MD · Gatroenterology department,Beijing Tong Ren Hospital, Capital Medical University

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-01
Primary Completion
2020-07-01
Completion
2021-07-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03600974 on ClinicalTrials.gov